Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report
Sherratt-Mayhew, Sam Nicolson, Phillip L R
Sherratt-Mayhew, Sam
Nicolson, Phillip L R
Citations
Altmetric:
Affiliation
University of Birmingham; University Hospitals Birmingham NHS Foundation Trust
Other Contributors
Publication date
2024-06-16
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Pure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune-related adverse event secondary to immune checkpoint inhibitor (ICI) therapy is rare. Steroids are usually used first line to treat ICI-induced PRCA. Here, we report a case of ICI-induced PRCA with no response to steroids but where intravenous (IV) immunoglobulin was successfully used second line. ICI therapy was reinitiated following PRCA resolution. PRCA recurrence did not occur.
Citation
Sherratt-Mayhew S, Nicolson PLR. Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report. EJHaem. 2024 Jun 16;5(4):825-828. doi: 10.1002/jha2.937.
Type
Report